Biomarkers for Treatment Response in Advanced Prostate Cancer
Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies—specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients...
Guardado en:
Autores principales: | Samia Asif, Benjamin A. Teply |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0fb3f4f5899244dd89585f92f0b83acd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
por: Maximilian Fleischmann, et al.
Publicado: (2021) -
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
por: Wojcik E, et al.
Publicado: (2017) -
T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Pichaya Thanindratarn, et al.
Publicado: (2021) -
The Role and Clinical Potentials of Circular RNAs in Prostate Cancer
por: Mohammad Taheri, et al.
Publicado: (2021) -
A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin
por: David S. Moura, et al.
Publicado: (2021)